Monthly Archives: April 2019

7 Stats to Know About Legal Cannabis and CBD This 4/20

7 Stats to Know About Legal Cannabis and CBD This 4/20

eCann Media is proud to showcase our portfolio of investments and subsidiaries. We have completed numerous investments across multiple verticals and sectors in the cannabis industry. Requesting an invitation will enable the eCann team to consider your eligibility for investment as well help us to identify the opportunities that best fit your needs and investment objectives.

Published at Sat, 20 Apr 2019 12:00:00 +0000

Tetra Bio Pharma Inc (OTCMKTS:TBPMF) Gets Shareholder Greenlight To Acquire Panag Pharma

Tetra Bio Pharma Inc (OTCMKTS:TBPMF) Gets Shareholder Greenlight To Acquire Panag Pharma

Tetra Bio Pharma Inc (OTCMKTS:TBPMF) announced on Thursday last week during a special shareholder meeting that its shareholders approved plans to acquire Panag Pharma.

The company also revealed that the acquisition approval also includes a greenlight for acceleration events that were included in the management information circular that shareholders received prior to the meeting. Panag is a Canadian firm that develops innovative cannabinoid-based treatments for inflammation and pain. Both Panag and Tetra have teamed up to carry out various pre-clinical studies targeting inflammatory conditions and ophthalmic pain. The acquisition will thus allow Panag to add value to Tetra’s operations.

“We have been working with Panag for over a year and as a combined entity we will have a robust product pipeline of cannabinoid derived drugs for development as prescription or OTC drugs,” stated Tetra CEO, Dr. Guy Chamberland.

The proposed transaction is still subject to various conditions despite the approval by shareholders and this includes a pending TSXV approval. The transaction scheduled to be finalized before April 30 this month.

Tetra and Ovensa collaborate to fight brain cancer

Tetra previously announced that it partnered with Ovensa to tackle brain cancer cells and they plan to do that by delivering cannabinoids into brain cancer cells using the TRIOZAN nanomedicine platform. Dr. Chamberland pointed out that Glioblastoma multiforme (GBM) is one of the most common brain cancer types and worse still, it happens to be fatal. Some of the notable individuals that have succumbed to it include the musician Gordon Downey and Senator John McCain.

The Tetra CEO also revealed that there have previously been some studies that demonstrate cannabinoid activities on brain tumors. If the two companies achieve success through the technology, then there is a chance that they will boost the treatment’s efficacy allowing it to be used as a supplement to chemotherapy and radiotherapy.

Takeda Pharmaceutical Co Ltd (NYSE:TAK) and Ovensas also announced a collaboration aimed at evaluating the TRIOZANÔ technology’s ability to deliver an antibody to the brain. The partnership is also part of an active cancer research program. The technology is designed to facilitate a high level of engineering flexibility as far as nanomedicines are concerned.

Published at Tue, 30 Apr 2019 12:01:00 +0000

CBD Unlimited Reaches 7.5 Million Wholesale Products Completion Milestone

CBD Unlimited Reaches 7.5 Million Wholesale Products Completion Milestone

CBD Unlimited, previously known as ENDEXX ORD (OTCMKTS:EDXC) announced a few days ago that it successfully achieved one of its major production milestones for 7.5 Million Wholesale Products to fulfill its initial demand requirements.

The announcement marks a major achievement for the company which deals with innovative phytonutrient food products as well as nutrients. The production milestone also marks another great quarter for CBD Unlimited and it hopes to achieve bigger targets before the end of 2019. The company has demonstrated its ability to run its production activities at full scale.

“Last year, we grew CBD Unlimited’s distribution to over 1,000 distribution channels. With full-scale production capabilities, we are confident that we will reach at least 5,000 by 2020,” stated Todd Davis, the Chairman, and CEO of CBD Unlimited.

The recently passed Farm Bill contributed to heavy market demand

Davis also noted that the Farm Bill which was passed into law in December last year played a role in the surging demand that the company experienced in Q1 2019. According to the CEO’s statement, the company’s national product reach has been growing. He also believes that this growth will allow the company to satisfy the high demand in the market. CBD Unlimited hopes to continue expanding its production capacity in line with the growing demand. The firm also expects demand to continue growing over the next two years.

CBD Unlimited has been nurturing a strong product portfolio

CBD Unlimited has two main technology products and services that it introduced in 2014, and two hemp-derived all-natural, consumable products that it develops and distributes to the market. One of the products is a trademarked, CBD-infused dog chew called Phyto-Bites. The product is designed to reduce inflammation, pain and separation anxiety.

The company recently introduced its Premium Blue Line CBD to retail customers in March this year during the 2019 ECRM Hemp/CBD Health & Beauty Care conference. The product is a duo-therapy and targeted-delivery product suite that features controlled dosing. The products have so far achieved a strong level of positive customer experience and can be fully scaled for mass market production as well as delivery.

Published at Mon, 29 Apr 2019 12:01:47 +0000

GOP Senator Says Congress Must Pass Marijuana Banking Bill That He’s Yet To Cosponsor

GOP Senator Says Congress Must Pass Marijuana Banking Bill That He’s Yet To Cosponsor

Sen. Mike Lee (R-UT) said in a new interview that the federal government’s national prohibition of marijuana doesn’t make sense and that Congress must, at a minimum, pass legislation to allow cannabis businesses to access financial institutions.

In an appearance on The Federalist Radio Show that was released on Friday, the senator was asked about the growing number of 2020 Democratic presidential candidates (except Joe Biden) who support marijuana legalization. Lee started by making a quip about how legalizing cannabis would lead to “more snowboarding, higher consumption of Doritos [and] Hostess products”—but then he got serious about the issue.

“We are at a weird inflection point,” he said. “If we were starting from a blank slate, I think it would always have made more sense for a thing like marijuana to have been regulated at a state level because this is a commodity that can be grown, harvested, packaged, sold and consumed entirely intrastate. And I think it probably would have made more sense to give the states the authority at the outset to make that decision on their own.”

The senator then talked about banking issues for the marijuana industry, saying that states have seen “an increase in duffle bags with $400,000 in cash making their rounds through the communities of Denver and elsewhere in Colorado because you cannot lawfully bank or electronically transfer money that is involved in marijuana.”

Published at Mon, 29 Apr 2019 20:38:19 +0000

Can Marijuana Stocks Maintain Their Forward Momentum?

Can Marijuana Stocks Maintain Their Forward Momentum?

The marijuana stock market has seen a large amount of upward sentiment over the course of the past year or so. With so many updates to the industry including changing legislation and the shifting public perception regarding the substance, it seems as though the current state of the market is the friendliest investor space we have seen in quite some time. Despite the fervent competition out there, there are some companies that have managed to make more headlines than others, and for good reason. Whether it be their business model or the amount of cannabis they can produce, innovation is continuing to lead the charge.

Ionic Brands Corp. (IONC) (IONC.C) is a company that has been working to produce large quantities of cannabis concentrates and products of the sort. Based out of Washington, they have managed to make quite a large name for themselves over the course of the time that they have been in business. Currently, in Washington state, they have stated that they are the #1 vaporizer brand domestically. Ionic Brands Corp. has also stated that they have been working to move deeper into the Oregon and California market on cannabis, which represents two of the largest individual cannabis spaces in the whole of the industry.

Recently, the company announced that they have signed a definitive agreement that would allow for the acquisition of Natural Extractions, a high-end edible and extraction company. The agreement shows that they will acquire the company, which is under the name Zoots, for around $855,000 and issuance of around 10.7 million common shares upon the closure of the transaction. After, the company will offer as many as 5.35 million common share warrants to those who currently own Zoots at a price of C$1.33 per share.

The acquisition of this company is quite important to the future of Ionic Brands as it allows them to move deeper into the cannabis concentrate market. For those who don’t know, Zoots states that they are a family owned, state-of-the-art edibles company based out of Washington State. The location of Zoots should also help to give them the utmost advantage when it comes to teamwork as they are located right nearby. All in all, Ionic Brands Inc. should remain on the radar for the coming future.

HEXO (NYSE:HEXO) is another cannabis company, but they are based out of Canada and specifically headquartered in the province of Quebec. The company has been working to up the amount of distribution potential that they have domestically, as well as the potential of a deal with a large investor.

HEXO has been working mainly to move into the top five producers of cannabis in Canada which is quite a large leap, but they look as though they have the potential to do so. Recently, they announced the purchase of Newstrike Brands for over $250 million. This is one of the largest mergers in the Canadian cannabis space since its inception, and we are still waiting to see what comes of it. HEXO continues to show the potential that they have in the marijuana market.

marijuana stocks acquisitions

Pursuant to an agreement between an affiliate of MAPH Enterprises, LLC (owners of MarijuanaStocks.com), Midam Ventures LLC and Ionic Brands Corp (IONC), Midam has been paid $50,000 from Ionic Brands Corp (IONC) for a period from April 2, 2019 to May 2, 2019. We may buy or sell additional shares of (IONC) in the open market at any time, including before, during or after the Website and Information, to provide public dissemination of favorable Information about Ionic Brands Corp (IONC).

Published at Mon, 29 Apr 2019 20:00:50 +0000

Chemesis International: The Global Cannabis Opportunity You Need To Be Watching

Chemesis International: The Global Cannabis Opportunity You Need To Be Watching

The landscape of the legal cannabis industry has changed, and this has led to significant opportunities for both companies and investors.

During the last year, we noticed a trend where investors began to focus more on the burgeoning cannabis opportunity in the United States as well as that in other emerging international markets (Australia, Europe, South America, and Africa). Although Canada has been leading the global cannabis movement, these emerging cannabis markets represent significant opportunities for companies to expand their reach.

Chemesis International (CSI: CSE) (CADMF: OTC) is a great example of a cannabis business that is focused on expansion and we are favorable on its growth prospects. When it comes to the United States, the company has been laser focused on the opportunity in California and that in Puerto Rico. Chemesis is also one of the only companies that is levered to the United States as well as South America, by way of its operation in Colombia.

The South American cannabis opportunity has been one of the most significant recent trends and we are favorable on the growth prospects associated with this market. The economics associated with cultivating cannabis in Colombia are very attractive and a significant feature of Chemesis’ long-term story.

Although we are of the opinion that the company’s Colombian operation will play a major role in its long-term story, we are most excited about its leverage to the United States in the near-term. Over the next year, we expect the operations in California to drive significant value and will monitor how the team is able to execute on this.

Capitalizing on the California Cannabis Concentrate Market

Last week, Chemesis reported a significant development in regard to its California operations and completed a definitive agreement to acquire 100% of a fully-operational and fully-licensed extraction and manufacturing facility in Cathedral City, California. We expect this acquisition to quickly prove to be accretive and are favorable on the impact it will have on the business. This acquisition will will bring the company’s processing ability to over 500,000 kg of cannabis per year and this represents a massive opportunity.

California is the world’s largest cannabis market and we are favorable on the leverage to this opportunity. The facility is generating revenue and is expected to further the company’s ability to extract cannabinoids (i.e. THC and CBD) and terpene products. Demand for cannabis concentrates continues to increase and this facility will enhance Chemesis’ leverage to this burgeoning vertical of the cannabis industry.

When it comes to the California cannabis opportunity, Chemesis is well positioned to become a major player in the cannabis concentrate market and we are excited about this. Last week, the company  also announced a binding agreement to increase its ownership interest in its flagship manufacturing facility in Cathedral City. Chemesis will acquire the remaining 20% ownership interest that it does not own and we are favorable on this move.

With these transactions, Chemesis will be able to provide additional third party manufacturing for brands that are in need of high-quality cannabis concentrates. The company will also be able to service its own brands (Jay & Silent Bob’s Private Stash and California Sap) through these facilities and we are favorable on this. Through its Desert Zen facility, the company also offers distribution and transportation services to cannabis brands which increases efficiency and reduces wait times for companies.

Enhances Leverage to Puerto Rico via a Significant Investment

In early April, Chemesis made a significant investment in GSRX Industries Inc. (GSRX) and acquired 19.9% of the business. This was a strategic investment that will enhance Chemesis’ leverage to California and Puerto Rico. This transaction is complementary to the company’s existing position in these markets as GSRX is focused on acquiring, developing and operating retail cannabis dispensaries in Puerto Rico and California.

Last week, GSRX announced that it expects to report strong second quarter results from its six operational dispensaries in California and Puerto Rico. GSRX has five owned-and-operated medical cannabis dispensaries in Puerto Rico and has one owned-and-operated Green Room dispensary in California. GSRX also operates one Pure and Natural retail kiosk and is in the process of launching two additional hemp based CBD retail outlets in Tennessee and Texas.

GSRX also reported strong numbers for the first three weeks of the second quarter and we are favorable on this. GSRX is forecasting significant growth for the second quarter and expects to generate approx. $3.3 – $3.5 million of revenue during the period. GSRX recently announced unaudited revenue numbers for the first quarter and reported to have generated $2.9 million in revenue during the period.

We are favorable on this relationship and believe that there are significant synergies between the two businesses. One of the reasons we are excited about this opportunity is due to the skills that each company brings to the table. Chemesis has extensive manufacturing, processing and extraction capabilities, which complements GSRX’s ability to professionally operate dispensaries and CBD stores. Another reason we are favorable on this relationship is due to the way it impacts the amount of people that Chemesis can reach. GSRX will expand the company’s footprint in strategic locations, specifically in Puerto Rico, California, Tennessee and Texas.

Under the agreement, Chemesis has a right of first refusal to manufacture GSRX’s current and future production requirements in all jurisdictions where Chemesis has production capabilities. GSRX will also make sure that each of its licensed locations has dedicated shelf space for Chemesis’ brands of products. This is an important part of the relationship and we will monitor how this potential revenue stream benefits Chemesis.

Focused on High-Margin Verticals  

Chemesis has been laser focused on the cannabis concentrate opportunity and we believe that this is something that is worth highlighting. During the last year, we have seen a significant increase in the demand for cannabis concentrates and this is a trend that we expect will continue.

Cannabis concentrates are used in products like vaporizers and edibles, which are two of the fastest growing verticals of the industry. The margins associated with these products are much higher when compared to the sale of cannabis flower and this is significant. Chemesis has been highly focused on this burgeoning opportunity and we are favorable on the growth prospects associated with this.

We will be monitoring how Chemesis executes on the cannabis concentrate market and believe that this could prove to be a major growth driver. The company utilizes a volatile BHO (Butane Hash Oil) extraction method that allows for rapid and efficient extraction of cannabinoids from trim. As a result, the company will be able to provide extraction services for THC & CBD products through both ethanol and BHO extraction processes.

The extraction method that the company uses will allow it to produce a unique variety of finished goods that can be varied to achieve desired potencies of different cannabinoids and terpenes. This is important since the company will be able to create a wide variety of cannabis products that appeal to consumers and we will monitor how this business evolves throughout the year.

In the Middle of a Major Expansion in Colombia

Chemesis has been highly focused on the Latin American cannabis opportunity and signed a definitive agreement to acquire La Finca Interacviva-Arachna Med SAS., an integrated cannabis company that has been operational since late 2017 and has access to over 1,000 acres of outdoor cultivation land.

Earlier this year, Chemesis announced that La Finca plans to commence construction of its GMP certified extraction facility which will also house a certified production lab. The facility will have a large production capacity for both domestic and international markets and this represents a significant opportunity for Chemesis. Once the company has constructed a GMP certified extraction facility, it will be able to export products to international cannabis markets and we will monitor how the team executes on this.

The Colombian cannabis market represents an attractive opportunity for Chemesis to produce high-quality low-cost cannabis concentrates. Over the next year, we expect to see a significant increase in demand for these products and Chemesis should be a beneficiary of this.

A Company to be Watching

During the last year, Chemesis International has significantly advanced its fundamental story and has accomplished this through a series of organic and inorganic growth initiatives. The company has been able to use its stock as a currency to make acquisitions and we are favorable on the growth prospects as a result of this. Chemesis is in the middle of a major expansion in California and Colombia and has attractive leverage to the opportunity in Puerto Rico.

Chemesis represents a multi-faceted growth opportunity that has leverage to some of the most exciting cannabis markets and we are bullish on its focus on the cannabis oil opportunity. One of the reasons why we are confident in Chemesis’ ability to execute is due to the strength of its management team and its balance sheet. The company is well capitalized and well positioned to execute on its previously announced growth initiatives.

We have been highlighting Chemesis since early 2018 and this is an opportunity we have been excited about. To learn more about Chemesis International, please contact support@technical420.com.

Pursuant to an agreement between StoneBridge Partners LLC and Chemesis International we have been hired for a period of 365 days beginning July 15, 2018 and ending July 15, 2019 to publicly disseminate information about (CSI) including on the Website and other media including Facebook and Twitter. We are being paid $5,000 per month for a period of 3 months. We own zero shares of (CSI), which we purchased in the open market. We plan to sell the “ZERO” shares of (CSI) that we hold during the time the Website and/or Facebook and Twitter Information recommends that investors or visitors to the website purchase without further notice to you. We may buy or sell additional shares of (CSI) in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information.

Share

Share - Facebook


Share - Twitter

Published at Thu, 25 Apr 2019 11:28:51 +0000

MJIC Announces New Northern California Distribution, Manufacturing and Delivery Facility

MJIC Announces New Northern California Distribution, Manufacturing and Delivery Facility

LOS ANGELES & SAN FRANCISCO–()–MJIC,
Inc
. (“MJIC” or the “Company”), California’s leading provider of
fully-licensed cannabis wholesale distribution, retail, compliance and
supply chain solutions, today announced its new fully-licensed,
multi-purpose facility in Brisbane, California, a strategic milestone in
the Company’s service expansion throughout the state and the San
Francisco Bay Area.

The 16,000-square-foot facility sits on the doorstep of both San
Francisco and Silicon Valley, and will allow MJIC to consolidate
licensed cannabis distribution, manufacturing, and delivery operations
in the heart of one of the state’s largest metropolitan areas.

It will also be a significant source of job creation, with MJIC
expecting to draw from the local talent pool in Brisbane and the broader
San Francisco Peninsula area to fill more than 50 full-time positions.

“MJIC’s Brisbane facility will have enormous benefits for the local
economy by creating permanent, well-paying jobs that will have a ripple
effect throughout the Bay Area,” said Dmitry Gordeychev, MJIC’s Chief
Operating Officer. “We are thrilled to join this business community and
would like to thank the City of Brisbane for its thought leadership in
welcoming responsible cannabis operators like MJIC.”

The facility will accommodate such manufacturing activities as
packaging, labeling, co-packing, infusion, bottling, and white-labeling
to augment the existing suite of services the Company offers to its
distribution clients throughout California. It will also allow MJIC to
be one of the first licensed operators to offer local on-demand delivery
to consumers in the Peninsula, while expanding the Company’s rapidly
growing distribution presence in Northern California.

“Our new Brisbane facility unlocks an expanded set of
business-to-business capabilities that MJIC can provide at the statewide
level, as well as on a localized basis in the Bay Area,” said
Gordeychev. We look forward to delivering the safest, highest-quality
cannabis products to the underserved Peninsula consumer.”

In connection with the facility, the Company has received a Conditional
Use Permit from the City of Brisbane, as well as temporary licenses for
distribution and non-storefront retail (delivery) from the State of
California Bureau of Cannabis Control and for manufacturing from the
State of California Department of Public Health.

Brisbane complements MJIC’s licensed facility in Oakland, which will
serve distribution clients and delivery customers throughout the East
Bay and North Bay regions. In addition, MJIC operates a licensed
distribution facility in Coachella, California and expects to commence
licensed distribution operations at its facility in Long Beach later
this year.

About MJIC, Inc.

MJIC, based Commerce, California, is the first fully-licensed and
integrated infrastructural and services platform for compliant cannabis.
The Company services the needs of lawful operators across the supply
chain, from the cultivator to the consumer, and from long-haul statewide
commerce to the local last mile. MJIC augments this business-to-business
value proposition with a growing portfolio of owned and operated retail
operations located in major metropolitan markets throughout California
and beyond, including brick-and-mortar dispensaries and local on-demand
delivery services, as well as e-commerce and subscription offerings. To
learn more, please visit: www.mjic.com.

Published at Tue, 08 Jan 2019 23:54:04 +0000

MJIC Announces New Northern California Distribution, Manufacturing and Delivery Facility

MJIC Announces New Northern California Distribution, Manufacturing and Delivery Facility

LOS ANGELES & SAN FRANCISCO–()–MJIC,
Inc
. (“MJIC” or the “Company”), California’s leading provider of
fully-licensed cannabis wholesale distribution, retail, compliance and
supply chain solutions, today announced its new fully-licensed,
multi-purpose facility in Brisbane, California, a strategic milestone in
the Company’s service expansion throughout the state and the San
Francisco Bay Area.

The 16,000-square-foot facility sits on the doorstep of both San
Francisco and Silicon Valley, and will allow MJIC to consolidate
licensed cannabis distribution, manufacturing, and delivery operations
in the heart of one of the state’s largest metropolitan areas.

It will also be a significant source of job creation, with MJIC
expecting to draw from the local talent pool in Brisbane and the broader
San Francisco Peninsula area to fill more than 50 full-time positions.

“MJIC’s Brisbane facility will have enormous benefits for the local
economy by creating permanent, well-paying jobs that will have a ripple
effect throughout the Bay Area,” said Dmitry Gordeychev, MJIC’s Chief
Operating Officer. “We are thrilled to join this business community and
would like to thank the City of Brisbane for its thought leadership in
welcoming responsible cannabis operators like MJIC.”

The facility will accommodate such manufacturing activities as
packaging, labeling, co-packing, infusion, bottling, and white-labeling
to augment the existing suite of services the Company offers to its
distribution clients throughout California. It will also allow MJIC to
be one of the first licensed operators to offer local on-demand delivery
to consumers in the Peninsula, while expanding the Company’s rapidly
growing distribution presence in Northern California.

“Our new Brisbane facility unlocks an expanded set of
business-to-business capabilities that MJIC can provide at the statewide
level, as well as on a localized basis in the Bay Area,” said
Gordeychev. We look forward to delivering the safest, highest-quality
cannabis products to the underserved Peninsula consumer.”

In connection with the facility, the Company has received a Conditional
Use Permit from the City of Brisbane, as well as temporary licenses for
distribution and non-storefront retail (delivery) from the State of
California Bureau of Cannabis Control and for manufacturing from the
State of California Department of Public Health.

Brisbane complements MJIC’s licensed facility in Oakland, which will
serve distribution clients and delivery customers throughout the East
Bay and North Bay regions. In addition, MJIC operates a licensed
distribution facility in Coachella, California and expects to commence
licensed distribution operations at its facility in Long Beach later
this year.

About MJIC, Inc.

MJIC, based Commerce, California, is the first fully-licensed and
integrated infrastructural and services platform for compliant cannabis.
The Company services the needs of lawful operators across the supply
chain, from the cultivator to the consumer, and from long-haul statewide
commerce to the local last mile. MJIC augments this business-to-business
value proposition with a growing portfolio of owned and operated retail
operations located in major metropolitan markets throughout California
and beyond, including brick-and-mortar dispensaries and local on-demand
delivery services, as well as e-commerce and subscription offerings. To
learn more, please visit: www.mjic.com.

Published at Tue, 08 Jan 2019 23:54:04 +0000

Spectrum Cannabis and the Arthritis Society Team Up to Launch Arthritis Talks, A National Symposium Series for Patients

Spectrum Cannabis and the Arthritis Society Team Up to Launch Arthritis Talks, A National Symposium Series for Patients

 Spectrum Cannabis, the medical division of Canopy Growth Corporation (TSX: WEED) (NYSE: CGC) is pleased to announce a partnership with the Arthritis Society to raise awareness and educate people about living with arthritis, including the potential of medical cannabis as a treatment for arthritis symptoms and the importance of seeking guidance from health care practitioners. The Arthritis Society is a leading charitable funder of arthritis research whose vision is to live in a world where people are free from the devastating effects of arthritis.

Logo: Spectrum Cannabis (CNW Group/Canopy Growth Corporation)

The partnership will engage Canadians across the country in a series of symposiums titled “Arthritis Talks,” presented by the Arthritis Society and Spectrum Cannabis. The series consists of a comprehensive program of in-person and digitally-accessible education events across Canadafeaturing leading speakers on topics that are of high interest and relevance to people living with arthritis.

Spectrum Cannabis and the Arthritis Society are also committed to creating a range of evidence-based resources that will enable people with arthritis to make informed decisions regarding medical cannabis. These resources which will be developed over the coming months and available on Arthritis.ca, range from infographics to educational videos and an online guide that will feature content backed by the latest evidence available to guide patients through the process of making decisions about medical cannabis.

Today, one in five people across Canada live with arthritis; that’s about six million Canadians and the prevalence of arthritis is on the rise. It’s estimated that as many as one in four Canadians will have arthritis by 2040, a projected 50% increase.

“Many people today have significant unmet medical needs, particularly with conditions such as arthritis where standard therapies have produced sub-par results,” commented Dr. Mark Ware, Chief Medical Officer, Canopy Growth. “Our partnership with the Arthritis Society aligns with our commitment to set the industry standard for awareness and education surrounding medical cannabis and its various therapeutic benefits including its potential as a treatment for those living with arthritis.”

“For people with arthritis, symptoms like chronic pain and fatigue can seriously erode your quality of life,” says Arthritis Society Chief Science Officer, Dr. Siân Bevan. “While medical cannabis may offer the possibility of some relief, these patients and their physicians need credible, evidence-based guidance with which to make informed treatment decisions. The Arthritis Society continues to lead the way in calling for and funding innovative research and education initiatives to address this urgent need, and we are pleased to partner with Spectrum Cannabis to empower Canadians living with arthritis to make the treatment decisions that are right for them.”

Arthritis Talks: Nourish & Flourish, the first event of this exciting series takes place on Saturday, May 4, 2019 in both Calgary and Winnipeg. Experts in nutrition, physical activity and medical cannabis will bring current research and information about arthritis to in-person attendees and online participants through a live, interactive webcast. Event information and registration instructions can be found on the Arthritis Society website.

Spectrum Cannabis: Medical Cannabis. Simplified.

About the Arthritis Society
The Arthritis Society is a national health charity, fueled by donors and volunteers, with a vision to live in a world where people are free from the devastating effects that arthritis has on lives. Begun in 1948 with one very clear goal – to alleviate the suffering of people crippled by arthritis – that same volunteer-led passion carries on today in communities across Canada. Through the trust and support of our donors and sponsors, the Arthritis Society is Canada’s largest charitable source of investments in cutting-edge arthritis research, proactive advocacy and innovative solutions that will deliver better health outcomes for people affected by arthritis. The Arthritis Society is accredited under Imagine Canada’s Standards Program. For more information and to make a donation, visit arthritis.ca.

About Spectrum Cannabis
Spectrum Cannabis, a wholly-owned subsidiary of Canopy Growth, is dedicated to simplifying medical cannabis for patients and healthcare practitioners worldwide. Founded in Canada, Spectrum Cannabis operates in Australia, South America, Africa and across Europe. Spectrum Cannabis products are available in a wide range of potencies and formats designed to simplify the dialogue around strength and dosage by applying a colour-coded Spectrum to categorize medical cannabis according to THC and CBD levels. Its product lineup includes whole flower cannabis, oils and new innovations such as Softgels. Through product simplification, easy dosing formats, and ongoing education of healthcare professionals, Spectrum Cannabis is committed to improving the lives of medical cannabis patients around the globe.

About Canopy Growth
Canopy Growth (TSX:WEED, NYSE:CGC) is a world-leading diversified cannabis and hemp company, offering distinct brands and curated cannabis varieties in dried, oil and Softgel capsule forms. Canopy Growth offers medically approved vaporizers through the Company’s subsidiary, Storz & Bickel GMbH & Co. KG. From product and process innovation to market execution, Canopy Growth is driven by a passion for leadership and a commitment to building a world-class cannabis company one product, site and country at a time. The Company has operations in over a dozen countries across five continents.

The Company is proudly dedicated to educating healthcare practitioners, conducting robust clinical research, and furthering the public’s understanding of cannabis, and through its wholly owned subsidiary, Canopy Health Innovations (“Canopy Health”), has devoted millions of dollars toward cutting edge, commercializable research and IP development. Canopy Growth works with the Beckley Foundation and has launched Beckley Canopy Therapeutics to research and develop clinically validated cannabis-based medicines, with a strong focus on intellectual property protection. Canopy Growth acquired assets of leading hemp research company, ebbu, Inc. (“ebbu”). Intellectual Property (“IP”) and R&D advancements achieved by ebbu’s team apply directly to Canopy Growth’s hemp and THC-rich cannabis genetic breeding program and its cannabis-infused beverage capabilities. Through partly owned subsidiary Canopy Rivers Corporation, the Company is providing resources and investment to new market entrants and building a portfolio of stable investments in the sector.

From our historic public listing on the Toronto Stock Exchange and New York Stock Exchange to our continued international expansion, pride in advancing shareholder value through leadership is engrained in all we do at Canopy Growth. Canopy Growth has established partnerships with leading sector names including cannabis icon Snoop Dogg, breeding legends DNA Genetics and Green House seeds, Battelle, the world’s largest nonprofit research and development organization, and Fortune 500 alcohol leader Constellation Brands, to name but a few. Canopy Growth operates ten licensed cannabis production sites with over 4.3 million square feet of production capacity, including over one million square feet of GMP certified production space. The Company operates Tweed retail stores in Newfoundland and Manitoba and has entered into supply agreements with every Canadian province and territory. For more information visit www.canopygrowth.com

Notice Regarding Forward Looking Statements
This news release contains “forward-looking statements” within the meaning of the United States Private Securities Litigation Reform Act of 1995 and “forward-looking information” within the meaning of applicable Canadian securities legislation. Often, but not always, forward-looking statements and information can be identified by the use of words such as “plans”, “expects” or “does not expect”, “is expected”, “estimates”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. Forward-looking statements or information involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Canopy Growth or its subsidiaries to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements or information contained in this news release. Examples of such statements include statements with respect to creation of digital educational assets and tools. Risks, uncertainties and other factors involved with forward-looking information could cause actual events, results, performance, prospects and opportunities to differ materially from those expressed or implied by such forward-looking information, including educational resources and events, and such risks contained in the Company’s annual information form dated June 27, 2018 and filed with Canadian securities regulators available on the Company’s issuer profile on SEDAR at www.sedar.com. Although the Company believes that the assumptions and factors used in preparing the forward-looking information or forward-looking statements in this news release are reasonable, undue reliance should not be placed on such information and no assurance can be given that such events will occur in the disclosed time frames or at all. The forward-looking information and forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking information or forward-looking information to reflect new information, subsequent events or otherwise unless required by applicable securities laws.

Cision

View original content to download multimedia:http://www.prnewswire.com/news-releases/spectrum-cannabis-and-the-arthritis-society-team-up-to-launch-arthritis-talks-a-national-symposium-series-for-patients-300838256.html

SOURCE Canopy Growth Corporation

Published at Thu, 25 Apr 2019 12:09:31 +0000

New Hampshire Senate Committee Supports ‘Home Grow’ Option for Medical Marijuana Program

New Hampshire Senate Committee Supports ‘Home Grow’ Option for Medical Marijuana Program

Baltimore, MD (April 24, 2019) – PRESS RELEASE – CANNOVIA, LLC, a new provider of pure, quality cannabidiol (CBD) products for better wellness to positively impact both the mind and body of all people and pets, has announced their official launch in the CBD industry becoming the newest brand to watch.

CANNOVIA farms, plants and harvests their hemp-derived CBD allowing control of the purity, quality and consistency of their products from seed to wellness. From high-altitude Colorado farms, their quality control process and investment in third-party testing, CANNOVIA ensures only the best products for their consumers.

“The hemp-CBD market alone could hit $22 billion by 2022, according to the Brightfield Group, so this is an exciting time for CANNOVIA to enter into the industry as it not only grows, but continues to evolve and develop. Coming into this emerging market with a background in healthcare and business, I am excited to optimize the commercial opportunities of CBD-infused items by providing consumers with quality and consistent CBD ingredients through a family of brands that fit all lifestyles,” stated Brian Baum, CEO of CANNOVIA.

As the brand itself launches in the CBD industry, they are also launching their first product line, the Founder’s Series, which is currently available for sale on CANNOVIA.COM. The Founder’s Series will feature four of CANNOVIA’s therapeutic products including CBD in the form of tinctures, beverage powder, muscle gel and lotion.

Dedicated to consistency, purity and quality in all their CBD-infused products, CANNOVIA is developing and offering a family of brands they hope consumers will trust and love. The CANNOVIA family of brands will also include a skincare line called Dazey Hemp which consists of all-natural CBD infused skincare products designed to rejuvenate and care for skin naturally and Mynd Gum, a line of CBD-infused gum. Both product lines are set to launch in stages throughout the coming months.

For more information on CANNOVIA and the natural benefits of CBD please visit https://cannovia.com/.

Published at Fri, 26 Apr 2019 19:14:00 +0000